Endothelial cell-based systemic gene therapy of metastatic melanoma

Cancer Gene Therapy

Volumn 8, Issue 9, 2001, Pages 636-648

  Ojeifo, John O ^a   Lee, Hyeran R ^a   Rezza, Phyllis ^a   Su, Ning ^a   Zwiebel, James A ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Endothelial cells; Gene therapy; Interleukin 2; Murine melanoma

Indexed keywords

BETA GALACTOSIDASE; FIBROBLAST GROWTH FACTOR; GENE PRODUCT; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFECT; ENDOTHELIUM CELL; GENE THERAPY; LYMPHOCYTE SUBPOPULATION; MELANOMA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SKIN METASTASIS; TARGET CELL; TRANSGENE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; BETA-GALACTOSIDASE; ENDOTHELIUM, VASCULAR; FEMALE; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-2; LAC OPERON; LUMINESCENT PROTEINS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; RETROVIRIDAE;

EID: 0034815664     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700356     Document Type: Article

References (65)

1. Cancer Statistics
2. Estimates of the worldwide mortality from twenty-five major cancers in 1990. Implications for prevention and projection of the future burden
3. Malignant tumors of the breast
4. Age-related prostate metastases
5. Angiogenesis research: From laboratory to clinic
6. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis
7. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
8. Tumor angiogenesis and metastases correlation in invasive breast carcinoma
9. Tumor angiogenesis correlation with metastasis in invasive prostate
10. Spectrum of tumor angiogenesis in bone marrow of the children with acute lymphoblastic leukemia
11. Angiogenesis-directed implantation of genetically modified endothelial cells in mice
12. Isolation of putative endothelial cells for angiogenesis
13. Endothelial cell implantation and survival within experimental gliomas
14. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
15. Drug delivery by genetically engineered cell implants
16. Gene therapy of metastatic cancer by in vivo retroviral gene targeting
17. Endothelial cells as vehicles for gene therapy
18. The complexity of endothelial cells
19. Towards endothelial cell-directed cancer immunotherapy: In vitro expression of human recombinant cytokine genes by human and mouse primary endothelial cells
20. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary
21. Effects of somatostatin, somatostatin analogs, and endothelial cell somatostatin gene transfer on smooth muscle cell proliferation in vitro
22. Breast cancer gene therapy: Transgenic immunotherapy
23. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
24. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases
25. The identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein
26. Synthesis of antihemophilic factor antigen by cultured human endothelial cells
27. Redesign of retrovirus packaging cell line to avoid recombination leading to helper virus production
28. Evaluation of a soluble tetrazolium formazan assay for cell growth and drug sensitivity in culture using human and other cell lines
29. Continuous proliferation of murine antigen-specific helper T lymphocytes in culture
30. The fate of interleukin 2 after in vivo administration
31. In vivo administration of purified human interleukin-2: II. Half-life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2
32. Principles of cancer management: Biologic therapy
33. Immunotherapy of tumor metastases via gene therapy
34. Loss of transporter in antigen processing I transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer
35. Interactions between the immune system and breast cancer
36. Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice
37. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors
38. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma
39. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector
40. Cytokine gene therapy of mesothelioma: Immune and antitumor effects of transfected interleukin-12
41. Gene gun-mediated skin transfection with interleukin-12 gene results in regression of established primary and metastatic murine tumors
42. Aphase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma
43. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-inteferon gene or admixed with conventional adjuvants
44. The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma
45. Tumor vasculature as a target for anticancer therapy
46. Antiangiogenic gene therapy
47. Gene therapy strategies for tumor angiogenesis
48. Generation of targeted retroviral vectors by using single chain variable fragment: An approach to in vivo gene delivery
49. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
50. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene
51. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
52. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression
53. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene
54. Biologic aspects of expression of stably integrated transgenes in cells of the skin in vitro and in vivo
55. Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity
56. Cellular suicide therapy of malignant disease
57. Drug delivery by genetically engineered cell implants
58. Adoptive cellular therapy
59. Evidence for circulating bone marrow derived endothelial cells
60. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculo-genesis in physiological and pathological neovascularization
61. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial cell progenitor cells for neovascularization
62. Blood-derived angioblasts accelerate blood flow restoration in diabetic mice
63. Transplantation of ex-vivo expanded endothelial cell progenitor cells for therapeutic neovascularization
64. Marrow-derived cell contribute to tumor neovasculature and when modified to express an angiogenesis inhibitor, restrict tumor growth in mice